

# 103 - References

## References

Schizophrenia and related psychoses CHAPTER 1 In practice, penfluridol is usually started at a dose of 20mg and increased to a maximum of 40mg after assessment. Steady-state levels are effectively reached after 2-3 weeks. Monitoring includes investigations of renal and hepatic function, changes in cardiometabolic parameter such as lipids, blood glucose, ECG and general adverse effect screening. Other antipsychotics which may be suitable for once-weekly oral administration include pimozide, aripiprazole and cariprazine.<sup>12</sup> References

1. Janssen PA, et al. The pharmacology of penfluridol (R 16341) a new potent and orally long-acting neuroleptic drug. *Eur J Pharmacol* 1970; 11:139-154.
2. Cooper SF, et al. Penfluridol steady-state kinetics in psychiatric patients. *Clin Pharmacol Ther* 1975; 18:325-329.
3. Migdalof BH, et al. Penfluridol: a neuroleptic drug designed for long duration of action. *Drug Metab Rev* 1979; 9:281-299.
4. Soares BG, et al. Penfluridol for schizophrenia. *Cochrane Database Syst Rev* 2006; (2):CD002923.
5. Iqbal MJ, et al. A long term comparative trial of penfluridol and fluphenazine decanoate in schizophrenic outpatients. *J Clin Psychiatry* 1978; 39:375-379.
6. Quitkin F, et al. Long-acting oral vs injectable antipsychotic drugs in schizophrenics: a one-year double-blind comparison in multiple episode schizophrenics. *Arch Gen Psychiatry* 1978; 35:889-892.
7. van der Lee APM, et al. The impact of antipsychotic formulations on time to medication discontinuation in patients with schizophrenia: a Dutch registry-based retrospective cohort study. *CNS Drugs* 2021; 35:451-460.
8. Dunnett D, et al. Evaluation of the effectiveness and acceptability of the long-acting oral antipsychotic penfluridol: illustrative case series. *J Psychopharmacol* 2021; 36:223-231.
9. van Praag HM, et al. Controlled trial of penfluridol in acute psychosis. *Br Med J* 1971; 4:710-713.
10. Shopsin B, et al. Penfluridol: an open phase III study in acute newly admitted hospitalized schizophrenic patients. *Psychopharmacology (Berl)* 1977; 55:157-164.
11. Munitz H, et al. Loading: a beneficial therapeutic effect using an oral long-acting drug, Penfluridol (SEMAP). A pilot study. *Isr J Psychiatry Relat Sci* 1986; 23:215-220.
12. Brissos S, et al. Weekly supervised administration of oral antipsychotics: an alternative to long-acting injections? *CNS Drugs* 2022; 36:315-325.
13. Bhattacharyya R, et al. Resurgence of penfluridol: merits and demerits. *Eastern J Psychiatry* 2015; 18:23-29.

14. Ashraf-Uz-Zaman M, et al. Analogs of penfluridol as chemotherapeutic agents with reduced central nervous system activity. *Bioorg Med Chem Lett* 2018; 28:3652–3657.
- 

Revision #1

Created 2026-01-04 20:12:32 UTC by Omar Ayman

Updated 2026-01-04 20:12:32 UTC by Omar Ayman